Insider Transactions in Q4 2021 at Igm Biosciences, Inc. (IGMS)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 31
2021
|
M Kathleen Behrens |
BUY
Grant, award, or other acquisition
|
Direct |
211
+8.5%
|
-
|
|
Dec 31
2021
|
Michael D Loberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
300
+50.0%
|
-
|
|
Dec 31
2021
|
Christina Teng Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
195
+0.53%
|
-
|
|
Dec 31
2021
|
Jakob Haldor Topsoe |
BUY
Grant, award, or other acquisition
|
Direct |
130
+0.23%
|
-
|
|
Dec 31
2021
|
Michael Stewart Lee Director |
BUY
Grant, award, or other acquisition
|
Direct |
130
+9.54%
|
-
|
|
Dec 31
2021
|
Redmile Group, LLC Director |
BUY
Grant, award, or other acquisition
|
Indirect |
130
+0.0%
|
-
|
|
Nov 15
2021
|
Lisa Lynn Decker CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,367
+49.55%
|
$259,175
$25.5 P/Share
|
|
Nov 15
2021
|
George Gauthier Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,367
+43.96%
|
$259,175
$25.5 P/Share
|
|
Nov 15
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,139
+23.64%
|
$253,475
$25.5 P/Share
|
|
Nov 15
2021
|
Fred Schwarzer CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
10,233
+28.18%
|
$255,825
$25.5 P/Share
|
|
Nov 15
2021
|
Misbah Tahir CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,086
+20.22%
|
$252,150
$25.5 P/Share
|
|
Nov 15
2021
|
Chris H Takimoto CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Nov 02
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,326
-30.25%
|
$67,626
$51.37 P/Share
|
|
Nov 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,174
-21.13%
|
$57,526
$49.78 P/Share
|
|
Nov 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|
|
Oct 06
2021
|
Michael D Loberg Director |
BUY
Bona fide gift
|
Indirect |
300
+50.0%
|
-
|
|
Oct 06
2021
|
Michael D Loberg Director |
SELL
Bona fide gift
|
Direct |
300
-100.0%
|
-
|
|
Oct 05
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,242
-28.89%
|
$79,488
$64.1 P/Share
|
|
Oct 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
1,258
-22.64%
|
$81,770
$65.91 P/Share
|
|
Oct 01
2021
|
Bruce Keyt CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+31.03%
|
$0
$0.93 P/Share
|